HomeAI · summaries
Storia in 8 fonti
Abivax rallies 36% as trial data ease safety fears over obefazimod
French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ulcerative colitis treatment.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Abivax seeks to ease safety concerns with new data, boosting shares
Safety concerns tied to Abivax's experimental bowel disease drug tanked company shares just weeks ago. But a new analysis sent them climbing.
- ·
cnbc.com
French biotech stock soars 25% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.
- ·
naftemporiki.gr
Άλμα 31% για τη γαλλική Abivax μετά τα νέα στοιχεία για το πειραματικό φάρμακο
Τα δεδομένα φαίνεται να καθησυχάζουν τις ανησυχίες των επενδυτών που είχαν προκαλέσει νωρίτερα μέσα στον μήνα οι αναφορές σε περιστατικά καρκίνου κατά τη
- ·
ilsole24ore.com
A Parigi vola Abivax, rassicurano i nuovi dati sul farmaco Obefazimod
Indicazioni positive per i pazienti affetti da colite ulcerosa refrattaria. La domanda di autorizzazione all'immissione in commercio dovrebbe essere presentata nel quarto trimestre
- ·
euronews.com
Abivax rallies 36% as trial data ease safety fears over obefazimod
French biotech company Abivax said new clinical trial data supports the safety and effectiveness of its experimental ulcerative colitis treatment.
- ·
it.euronews.com
Abivax balza del 36%: i dati riducono i timori su obefazimod
La società francese di biotecnologia Abivax ha dichiarato che i nuovi dati degli studi clinici confermano sicurezza ed efficacia del suo trattamento sperimentale contro la colite…
- ·
benzinga.com
Why Is Abivax Stock Skyrocketing Tuesday? - Abivax (NASDAQ:ABVX)
Abivax (ABVX) stock skyrockets 36% following strong Phase 3 maintenance data for its ulcerative colitis treatment. Get the latest details.
- ·
endpoints.news
Abivax aims to set cancer concerns with ulcerative colitis drug to rest
Abivax says new Phase 3 data show cancer rates within expected range for its UC drug obefazimod, though Jefferies flags lingering FDA risk.